Oral PCSK9 Inhibitor Enlicitide Slashes LDL Cholesterol by Over 56 Percent in Pooled Trial Analysis
A pooled analysis of three randomized controlled trials shows the oral PCSK9 inhibitor enlicitide reduces LDL cholesterol by more than 56 percent with acceptable short-term safety. Subject of Research: Efficacy and safety of the oral PCSK9 inhibitor enlicitide in hypercholesterolemia Article Title: Efficacy…